ARPA-H awarded Linnaeus Therapeutics up to $21.9 million to test a GPER agonist for aging outcomes.

Provenance

First verified

2026-02-24

Last verified

2026-08-08

Version

1.0

Fingerprint

b94b3f8f37ce3218

Change sensitivity

Medium

Correction state

No correction

Interpretation boundary

Primary source

https://arpa-h.gov/explore-funding/awards/4196

Related signals

• SIG-2026-020 — PROSPR funds GPER agonist development to test improvement in aging outcomes